Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 17 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 11186625

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  2. US 11185585

    Methods and compositions for improving antiangiogenic therapy with anti-integrins

    The Regents of the University of California · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  3. US 11186611

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  4. US 11180540

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  5. US 11180492

    Anti-parasitic compounds and uses thereof

    The Regents of the University of California · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  6. CA 3177888

    ANTICORPS ANTI-HEMOJUVELINE (HJV) DE TRAITEMENT DE L'ANEMIE DE MALADIES CHRONIQUES

    DISC MEDICINE INC [US] · Granted Nov 18, 2021 · Expires Nov 13, 2041

    granted
  7. US 11174283

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  8. US 11174316

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  9. US 11168144

    Activatable anti-PDL1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  10. US 11161876

    Anti-inflammatory nanofibers

    Northwestern University · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  11. US 11161826

    Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

    ACADIA Pharmaceuticals Inc. · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  12. US 11155633

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  13. US 11155621

    Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  14. US 11149025

    Anti-cancer compounds

    The Regents of the University of California · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted
  15. US 11141479

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  16. US 11142578

    Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  17. US 11142530

    Deep-sea fungus-derived anthraquinone compound and use thereof in preparing anti-allergic drugs

    China Ocean Mineral Resources R&D Association · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  18. US 11124567

    Anti-TREM2 antibodies and methods of use thereof

    DENALI THERAPEUTICS INC. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  19. US 11124768

    Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

    Northwest Biotherapeutics, Inc. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  20. US 11117968

    Activatable anti-CTLA-4 antibodies and uses thereof

    CytomX Therapeutics, Inc. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  21. US 11117975

    Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  22. US 11118180

    Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  23. US 11117955

    Anti-Zika virus antibodies and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  24. US 11111309

    Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4

    Dyne Therapeutics, Inc. · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted